How tenofovir disoproxil fumarate can impact on solubility and dissolution rate of efavirenz?

被引:15
|
作者
Bazzo, Giovana Carolina [1 ]
Mostafa, Dina [1 ]
Franca, Maria Terezinha [1 ]
Pezzini, Bianca Ramos [1 ]
Stulzer, Hellen Karine [1 ]
机构
[1] Univ Fed Santa Catarina, Programa Posgrad Farm, Campus Trindade, BR-88040970 Florianopolis, SC, Brazil
关键词
Efavirenz; Tenofovir disoproxil fumarate; Solubility; Dissolution; Eutectic mixture; DRUG-DELIVERY SYSTEM; SOLID FORMS; ENHANCEMENT; CYCLODEXTRIN; MECHANISMS; BEHAVIOR; DESIGN;
D O I
10.1016/j.ijpharm.2019.118597
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Efavirenz (EFZ) and tenofovir disoproxil fumarate (TDF) can be used simultaneously in the treatment of human immunodeficiency virus type1 infection. In this work the impact of TDF, a hydrophilic drug, on the solubility and dissolution rate of EFZ, a poorly water-soluble drug, was evaluated. EFZ/TDF binary mixtures in different molar ratios were prepared. Differential scanning calorimetry (DSC) results indicate the formation of a eutectic mixture, the molar ratio of 65/35 being the eutectic point. It was observed an increase in the EFZ solubility in water and acidic conditions (0.1 N HCl and biorelevant medium), in the presence of TDF. On the other hand, there was a decreasing on EFZ solubility in phosphate buffer pH 6.8, probably influenced by the lower solubility of TDF in this medium. The high solubility of TDF in water and acidic medium may have contributed to improve the solubility of EFZ, as well as the formation of a eutectic mixture, supported by X-ray powder diffraction (XRPD) and Fourier Transform infrared spectroscopy (FTIR) analyses. However, TDF solubility and dissolution rate was not significantly influenced by the presence of EFZ.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Urinary β2 microglobulin can predict tenofovir disoproxil fumarate-related renal dysfunction in HIV-1-infected patients who initiate tenofovir disoproxil fumarate-containing antiretroviral therapy
    Nishijima, Takeshi
    Kurosawa, Takuma
    Tanaka, Noriko
    Kawasaki, Yohei
    Kikuchi, Yoshimi
    Oka, Shinichi
    Gatanaga, Hiroyuki
    AIDS, 2016, 30 (10) : 1563 - 1571
  • [32] Concurrent estimation of lamivudine, tenofovir disoproxil fumarate, and efavirenz in blended mixture and triple combination tablet formulation by a new stability indicating RP-HPLC method
    Godela, Ramreddy
    Kammari, Vijayalaxmi
    Gummadi, Sowjanya
    Beda, Durgaprasad
    FUTURE JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 7 (01)
  • [33] Concurrent estimation of lamivudine, tenofovir disoproxil fumarate, and efavirenz in blended mixture and triple combination tablet formulation by a new stability indicating RP-HPLC method
    Ramreddy Godela
    Vijayalaxmi Kammari
    Sowjanya Gummadi
    Durgaprasad Beda
    Future Journal of Pharmaceutical Sciences, 7
  • [34] Wavelet Signal Processing Tools for Quantifying and Monitoring the in-vitro Dissolution Profiles of Tenofovir Disoproxil Fumarate and Emtricitabine in Tablets
    Dinc, Erdal
    Ozdemir, Nurten
    Ostiindag, Ozgiir
    Buker, Eda
    Tilkan, Gunseli
    Hoang, Vu Dang
    JOURNAL OF THE MEXICAN CHEMICAL SOCIETY, 2022, 66 (04) : 488 - 499
  • [35] Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults
    Grant, Philip M.
    Kitch, Douglas
    McComsey, Grace A.
    Tierney, Camlin
    Ha, Belinda
    Brown, Todd T.
    HIV CLINICAL TRIALS, 2015, 16 (02): : 66 - 71
  • [36] Switching from Tenofovir Disoproxil to Tenofovir Alafenamide Fumarate: Impact on Cardiovascular Risk and Lipid Profile in People Living with HIV, an Observational Study
    Moschopoulos, Charalampos D.
    Protopapas, Konstantinos
    Thomas, Konstantinos
    Kavatha, Dimitra
    Papadopoulos, Antonios
    Antoniadou, Anastasia
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2023, 39 (02) : 68 - 75
  • [37] Estimated glomerular filtration rate partially recovered in patients without Hypertriglyceridemia during Tenofovir disoproxil fumarate treatment
    Pan, Ya-ru
    Liu, Si-qi
    He, Yi-shan
    Xue, Yuan
    Wang, Jian
    Huang, Rui
    Wu, Chao
    Lu, Jian-chun
    Liu, Long-gen
    ANNALS OF MEDICINE, 2023, 55 (01) : 760 - 765
  • [38] Real-Life Impact on Lipid Profile of a Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected Patients
    Lagoutte-Renosi, Jennifer
    Flammang, Mylene
    Chirouze, Catherine
    Beck-Wirth, Genevieve
    Bozon, Fabienne
    Brunel, Anne-Sophie
    Drobacheff-Thiebaut, Marie-Christine
    Foltzer, Adeline
    Hustache-Mathieu, Laurent
    Kowalczyk, Jakub
    Michel, Catherine
    Davani, Siamak
    Muret, Patrice
    CURRENT HIV RESEARCH, 2021, 19 (01) : 84 - 89
  • [40] Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment
    Wilkins, Ed L.
    Cohen, Calvin J.
    Trottier, Benoit
    Esser, Stefan
    Smith, Don E.
    Haas, Bernhard
    Brinson, Cynthia
    Garner, Will
    Chuck, Susan
    Thorpe, David
    De-Oertel, Shampa
    AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2016, 28 (03): : 401 - 408